High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Magnussen, Gry I ^a   Hellesylt, Ellen ^a   Nesland, Jahn M ^a   Trope, Claes G ^a   Flørenes, Vivi A ^a   Holm, Ruth ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Biomarkers; Targeted therapy; Treatment; Vulvar squamous cell carcinoma; Wee1

Indexed keywords

PHOSPHOTRANSFERASE; PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WEE1; CELL CYCLE PROTEIN; NUCLEAR PROTEIN; PROTEIN TYROSINE KINASE; TUMOR MARKER; WEE1 PROTEIN, HUMAN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CELL CYCLE; CELL VIABILITY; DNA DAMAGE; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; VULVA CARCINOMA; WESTERN BLOTTING; BIOSYNTHESIS; DISEASE COURSE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY; VULVA TUMOR;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROTEIN-TYROSINE KINASES; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; VULVAR NEOPLASMS;

EID: 84878893650     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-288     Document Type: Article

References (33)

1. Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006, 107:1018-1022. 10.1097/01.AOG.0000210268.57527.a1, 16648405.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236. 10.3322/caac.20121, 21685461.
3. Canavan TP, Cohen D. Vulvar cancer. Am Fam Physician 2002, 66:1269-1274.
4. Jones RW, Baranyai J, Stables S. Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol 1997, 90:448-452. 10.1016/S0029-7844(97)00298-6, 9277660.
5. Coulter J, Gleeson N. Local and regional recurrence of vulval cancer: management dilemmas. Best Pract Res Clin Obstet Gynaecol 2003, 17:663-681. 10.1016/S1521-6934(03)00050-6, 12965138.
6. Kuntz K, O'Connell MJ. The G(2) DNA damage checkpoint: could this ancient regulator be the Achilles heel of cancer?. Cancer Biol Ther 2009, 8:1433-1439.
7. Beck H, Nahse-Kumpf V, Larsen MS, O'Hanlon KA, Patzke S, Holmberg C, Mejlvang J, Groth A, Nielsen O, Syljuasen RG, Sorensen CS. Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption. Mol Cell Biol 2012, 32:4226-4236. 10.1128/MCB.00412-12, 3457333, 22907750.
8. Dominguez-Kelly R, Martin Y, Koundrioukoff S, Tanenbaum ME, Smits VA, Medema RH, Debatisse M, Freire R. Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease. J Cell Biol 2011, 194:567-579. 10.1083/jcb.201101047, 3160579, 21859861.
9. Iorns E, Lord CJ, Grigoriadis A, McDonald S, Fenwick K, Mackay A, Mein CA, Natrajan R, Savage K, Tamber N, Reis-Filho JS, Turner NC, Ashworth A. Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One 2009, 4:e5120. 10.1371/journal.pone.0005120, 2663812, 19357772.
10. Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A, Florenes VA. High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS One 2012, 7:e38254. 10.1371/journal.pone.0038254, 3373567, 22719872.
11. Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, Niers JM, Van Tilborg AA, Zwinderman AH, Geerts D, Kaspers GJ, Peter VW, Cloos J, Tannous BA, Wesseling P, Aten JA, Noske DP, Van Noorden CJ, Wurdinger T. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 2010, 18:244-257. 10.1016/j.ccr.2010.08.011, 3115571, 20832752.
12. PosthumaDeBoer J, Wurdinger T, Graat HC, van Beusechem VW, Helder MN, van Royen BJ, Kaspers GJ. WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer 2011, 11:156. 10.1186/1471-2407-11-156, 3103478, 21529352.
13. Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 2004, 15:252-256. 10.1093/annonc/mdh073, 14760118.
14. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009, 105:103-104. 10.1016/j.ijgo.2009.02.012, 19367689.
15. Kleihues PSL. Pathology and genetics of tumors of the breast and female genital organs 2003, 316-321. World Health Organization of Tumors: World Health Organization of Tumors, IARC Press.
16. Wang Z, Nesland JM, Suo Z, Trope CG, Holm R. The prognostic value of 14-3-3 isoforms in vulvar squamous cell carcinoma cases: 14-3-3beta and epsilon are independent prognostic factors for these tumors. PLoS One 2011, 6:e24843. 10.1371/journal.pone.0024843, 3174199, 21935479.
17. Wang Z, Trope CG, Florenes VA, Suo Z, Nesland JM, Holm R. Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes. BMC Cancer 2010, 10:233. 10.1186/1471-2407-10-233, 2887779, 20500813.
18. Knopp S, Bjorge T, Nesland JM, Trope C, Holm R. Cyclins D1, D3, E, and A in vulvar carcinoma patients. Gynecol Oncol 2005, 97:733-739. 10.1016/j.ygyno.2005.03.025, 15894358.
19. Knopp S, Bjorge T, Nesland JM, Trope C, Scheistroen M, Holm R. p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas. Gynecol Oncol 2004, 95:37-45. 10.1016/j.ygyno.2004.07.026, 15385108.
20. Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010, 24:679-686. 10.1038/leu.2010.6, 20130602.
21. Eom M, Han A, Lee MJ, Park KH. Expressional Difference of RHEB, HDAC1, and WEE1 Proteins in the Stromal Tumors of the Breast and Their Significance in Tumorigenesis. Korean J Pathol 2012, 46:324-330. 10.4132/KoreanJPathol.2012.46.4.324, 3479826, 23110024.
22. Bhattacharya A, Schmitz U, Wolkenhauer O, Schonherr M, Raatz Y, Kunz M. Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma 2012, Epud: Oncogene.
23. Davies KD, Cable PL, Garrus JE, Sullivan FX, von Carlowitz I, Huerou YL, Wallace E, Woessner RD, Gross S. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation. Cancer Biol Ther 2011, 12:788-796. 10.4161/cbt.12.9.17673, 21892012.
24. Hashimoto O, Shinkawa M, Torimura T, Nakamura T, Selvendiran K, Sakamoto M, Koga H, Ueno T, Sata M. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer 2006, 6:292. 10.1186/1471-2407-6-292, 1770931, 17177986.
25. Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok S. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther 2012, 11:174-182. 10.1158/1535-7163.MCT-11-0529, 22084170.
26. Sorensen CS, Syljuasen RG. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res 2011, 40:477-486. 3258124, 21937510.
27. Hermeking H, Benzinger A. 14-3-3 proteins in cell cycle regulation. Semin Cancer Biol 2006, 16:183-192. 10.1016/j.semcancer.2006.03.002, 16697662.
28. Beck H, Nahse V, Larsen MS, Groth P, Clancy T, Lees M, Jorgensen M, Helleday T, Syljuasen RG, Sorensen CS. Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase. J Cell Biol 2010, 188:629-638. 10.1083/jcb.200905059, 2835936, 20194642.
29. Fung TK, Poon RY. A roller coaster ride with the mitotic cyclins. Semin Cell Dev Biol 2005, 16:335-342. 10.1016/j.semcdb.2005.02.014, 15840442.
30. Leijen S, Beijnen JH, Schellens JH. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol 2010, 5:186-191. 10.2174/157488410791498824, 20406171.
31. Rajeshkumar NV, De OE, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A, Hidalgo M. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011, 17:2799-2806. 10.1158/1078-0432.CCR-10-2580, 3307341, 21389100.
32. Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, Sun Y. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res 2001, 61:8211-8217.
33. Choschzick M, Hantaredja W, Tennstedt P, Gieseking F, Wolber L, Simon R. Role of TP53 mutations in vulvar carcinomas. Int J Gynecol Pathol 2011, 30:497-504. 10.1097/PGP.0b013e3182184c7a, 21804386.